Biology of gastrointestinal stromal tumors.

By Christopher Corless, J. Fletcher, M. Heinrich. Journal of Clinical Oncology, 2004

1,198 citations recorded by the source corpus.

Subfields: Gastroenterology, Neurology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/c15abb52fa1c34544555b6620c3b53f825ea86db

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Gastroenterology

1. Christopher Corless
2. Heikki Joensuu
3. M. Heinrich
4. J. Fletcher
5. C. Fletcher

In Neurology

1. Heikki Joensuu

In Pulmonary and Respiratory Medicine

1. Heikki Joensuu
2. Christopher Corless
3. M. Heinrich

Citations in the corpus

• Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. (2005, neutral): “val, under imatinib treatment [40–42].”
• The crucial role of protein phosphorylation in cell signaling and its use as targeted therapy (Review) (2017, neutral): “Alteration of the phosphoproteome also affects gastrointestinal stromal tumors (GISTs) (98,99), lung cancer (73,100), hematologic malignancies (101,102), breast cancer (103,104), pancreatic cancer (105,106) and prostate cancer (103,107).”
• Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. (2006, background): “Conclusion Different molecular mechanisms are responsible for primary and secondary imatinib resistance in GISTs.”
• The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. (2006, background): “Interestingly, imatinib, a potent KIT inhibitor and now the standard frontline therapy for advanced gastrointestinal stromal tumors (39, 40) binds to an inactive conformation of KIT (38).”